M. Levit

发表

Receptor Methylation Controls the Magnitude of Stimulus-Response Coupling in Bacterial Chemotaxis*

J. Stock, M. Levit, 2002, The Journal of Biological Chemistry.

Active Site Interference and Asymmetric Activation in the Chemotaxis Protein Histidine Kinase CheA*

M. Surette, J. Stock, Y. Liu, 1996, The Journal of Biological Chemistry.

Dimerization Is Required for the Activity of the Protein Histidine Kinase CheA That Mediates Signal Transduction in Bacterial Chemotaxis (*)

M. Surette, J. Stock, M. Levit, 1996, The Journal of Biological Chemistry.

Information Processing in Bacterial Chemotaxis

J. Stock, P. Wolanin, M. Levit, 2002, Science's STKE.

Signal transduction: Hair brains in bacterial chemotaxis

J. Stock, M. Levit, Jeff Stock, 2000, Current Biology.

Stimulus response coupling in bacterial chemotaxis: receptor dimers in signalling arrays

J. Stock, Y. Liu, M. Levit, 1998, Molecular microbiology.

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

G. Nabel, D. Wiederschain, Huawei Qiu, 2022, Nature.

Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.

Neil D. Moorcroft, M. Levit, C. Barberis, 2017, Bioorganic & medicinal chemistry letters.

Concomitant Inhibition of PI 3 K b andBRAForMEK in PTEN-De fi cient / BRAF-Mutant Melanoma Treatment : Preclinical Assessment of SAR 260301 Oral PI 3 K b-Selective Inhibitor H el

C. García-echeverría, C. Lengauer, L. Vincent, 2016 .

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor

C. García-echeverría, C. Lengauer, L. Vincent, 2016, Molecular Cancer Therapeutics.

Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors - Lead optimization - Part III.

M. Levit, John Jiang, C. Barberis, 2019, Bioorganic & medicinal chemistry letters.

Discovery of N-substituted 7-azaindoles as Pan-PIM kinase inhibitors - Lead series identification - Part II.

Neil D. Moorcroft, M. Levit, C. Barberis, 2017, Bioorganic & medicinal chemistry letters.

Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation

D. Wiederschain, C. Winter, L. Schweizer, 2017, Oncotarget.

Catalysis of DNA cleavage and nucleoside triphosphate synthesis by NM23-H2/NDP kinase share an active site that implies a DNA repair function.

S. Kyin, M. Levit, E. Postel, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models

G. Nabel, D. Wiederschain, U. Şahin, 2021, Science Translational Medicine.

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade

A. Protopopov, D. Wiederschain, C. Winter, 2020, Oncoimmunology.

PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.

S. Gross, Q. Gao, D. Wiederschain, 2014, Blood.

suppression of STAT 5 activation and degradation of MYC oncogene PIM inhibitors target CD 25-positive AML cells through concomitant

S. Gross, Q. Gao, D. Wiederschain, 2014 .

SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

A. Zilberstein, P. Casellas, M. Levit, 2013, Leukemia & lymphoma.

SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, C. García-echeverría, L. Debussche, 2020, Molecular Cancer Therapeutics.

MOLECULAR CANCER THERAPEUTICS | SMALL MOLECULE THERAPEUTICS SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, L. Debussche, M. Levit, 2020 .

pH sensing in bacterial chemotaxis.

J. Stock, M. Levit, 1999, Novartis Foundation symposium.

Interactions between Escherichia coliNucleoside-diphosphate Kinase and DNA*

J. Stock, M. Levit, E. Postel, 2002, The Journal of Biological Chemistry.

Organization of the Receptor-Kinase Signaling Array That Regulates Escherichia coli Chemotaxis*

J. Stock, M. Levit, T. Grebe, 2002, The Journal of Biological Chemistry.

Mechanism of CheA protein kinase activation in receptor signaling complexes.

J. Stock, M. Levit, Y. Liu, 1999, Biochemistry.

Two-component signal transduction systems : structure-function relationships and mechanisms of catalysis

M. Surette, J. Stock, M. Levit, 1995 .

Discovery of SARxxxx92, a pan-PIM kinase Inhibitor, efficacious in a KG1 tumor model.

M. Levit, C. Barberis, Shih-Min A. Huang, 2020, Bioorganic & medicinal chemistry letters.

Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

M. Mathieu, C. García-echeverría, M. Levit, 2019, Journal of medicinal chemistry.

Abstract 943: SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer

C. García-echeverría, C. Winter, L. Debussche, 2018, Endocrinology.

Receptor‐mediated protein kinase activation and the mechanism of transmembrane signaling in bacterial chemotaxis

M. Surette, J. Stock, R. Lurz, 1997, The EMBO journal.

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections

J. Mascola, M. Connors, R. Koup, 2023, Nature communications.

Subunit Organization in a Soluble Complex of Tar, CheW, and CheA by Electron Microscopy*

Tanvir R. Shaikh, D. DeRosier, J. Stock, 2002, The Journal of Biological Chemistry.

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor

C. García-echeverría, C. Lengauer, L. Vincent, 2016, Molecular Cancer Therapeutics.

Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.

Neil D. Moorcroft, M. Levit, C. Barberis, 2017, Bioorganic & medicinal chemistry letters.